Codexis Inc. (CDXS)

15.39
NASDAQ : Process Industries
Prev Close 15.05
Day Low/High 14.93 / 15.40
52 Wk Low/High 12.68 / 23.05
Avg Volume 422.50K
Exchange NASDAQ
Shares Outstanding 58.52M
Market Cap 874.84M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Codexis To Hold Third Quarter 2019 Conference Call On November 5

Codexis To Hold Third Quarter 2019 Conference Call On November 5

REDWOOD CITY, Calif., Oct.

Codexis' Protein Engineering Forum Highlights Progress And Future Direction Of The Field

Codexis' Protein Engineering Forum Highlights Progress And Future Direction Of The Field

Industry and academic leaders convened to discuss the direction of protein engineering for a wide range of applications

Codexis Spreading The Promise Of Engineered Proteins At SynBioBeta Summit

Codexis Spreading The Promise Of Engineered Proteins At SynBioBeta Summit

Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, is contributing resources and expertise to communicate protein engineering's vast potential at SynBioBeta's Global Synthetic Biology Summit in San Francisco, Oct.

Codexis To Present At The 2019 Cantor Fitzgerald Global Healthcare Conference

Codexis To Present At The 2019 Cantor Fitzgerald Global Healthcare Conference

REDWOOD CITY, Calif., Sept.

CDXS: Insiders Vs. Shorts

CDXS: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and Codexis Inc is one of the most shorted stocks of the Russell 3000, based on 14.38 "days to cover" versus the median component at 5.30. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Codexis Reports Second Quarter 2019 Financial Results

Codexis Reports Second Quarter 2019 Financial Results

Product revenue up 68%; R&D revenue spread over wider base of customers and markets Conference call begins at 4:30 pm Eastern time today REDWOOD CITY, Calif.

Codexis Names Ross Taylor Senior Vice President And Chief Financial Officer

Codexis Names Ross Taylor Senior Vice President And Chief Financial Officer

CFO Gordon Sangster announces retirement

Oversold Conditions For Codexis (CDXS)

Oversold Conditions For Codexis (CDXS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Codexis To Hold Second Quarter 2019 Conference Call On August 6

Codexis To Hold Second Quarter 2019 Conference Call On August 6

REDWOOD CITY, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc.

CDXS Crosses Below Key Moving Average Level

CDXS Crosses Below Key Moving Average Level

In trading on Wednesday, shares of Codexis Inc crossed below their 200 day moving average of $18.43, changing hands as low as $18.18 per share. Codexis Inc shares are currently trading off about 5.3% on the day.

First Week Of February 15th Options Trading For Codexis (CDXS)

First Week Of February 15th Options Trading For Codexis (CDXS)

Investors in Codexis Inc saw new options begin trading this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CDXS options chain for the new February 15th contracts and identified the following put contract of particular interest.

Codexis Reaches Analyst Target Price

Codexis Reaches Analyst Target Price

In recent trading, shares of Codexis Inc have crossed above the average analyst 12-month target price of $17.50, changing hands for $18.05/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

CDXS Crosses Above Average Analyst Target

CDXS Crosses Above Average Analyst Target

In recent trading, shares of Codexis Inc have crossed above the average analyst 12-month target price of $17.40, changing hands for $17.54/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Codexis Reaches Analyst Target Price

Codexis Reaches Analyst Target Price

In recent trading, shares of Codexis Inc have crossed above the average analyst 12-month target price of $14.70, changing hands for $15.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

CDXS Crosses Above Average Analyst Target

CDXS Crosses Above Average Analyst Target

In recent trading, shares of Codexis Inc have crossed above the average analyst 12-month target price of $14.70, changing hands for $15.00/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Porton Pharma Solutions And Codexis Launch Global Partnership

Porton Pharma Solutions And Codexis Launch Global Partnership

Codexis, Inc. (NASDAQ: CDXS) and Porton Pharma Solutions, Ltd.

Codexis Reaches Analyst Target Price

Codexis Reaches Analyst Target Price

In recent trading, shares of Codexis Inc have crossed above the average analyst 12-month target price of $10.00, changing hands for $10.40/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Codexis Reaches Analyst Target Price

Codexis Reaches Analyst Target Price

In recent trading, shares of Codexis Inc have crossed above the average analyst 12-month target price of $8.50, changing hands for $8.80/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

TheStreet Quant Rating: D (Sell)